BofA raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Buy rating on the shares. The firm is positive on the company’s decision to remain disciplined on the external growth front, but acknowledges the markets concern that it may fall behind as others shift to an offensive strategy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: